Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06534060 · ClinicalTrials.gov registry record · Phase 2
MB-105 in Patients With CD5 Positive T-cell Lymphoma
A Phase 2 study of Lymphoma, T-Cell, sponsored by March Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 12
- Study locations
NCT06534060: Recruiting Phase 2 study of Lymphoma, T-Cell, sponsored by March Biosciences.
NCT06534060 is a Phase 2 study of Lymphoma, T-Cell that is actively recruiting participants, run by March Biosciences. The registered enrollment target is 46 participants, below the 121-participant average among 9 other Lymphoma, T-Cell trials with a reported enrollment target (62% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06534060, a Phase 2 study of Lymphoma, T-Cell, is actively recruiting participants, sponsored by March Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Primary Outcome
Incidence, severity, causal relationship of AEs
Conditions Studied
Interventions
- BIOLOGICAL Genetic: MB-105
Study Locations (12)
Texas
- Baylor College of Medicine - Houston
- MD Anderson Cancer Center - Houston
California
- University of San Diego (UCSD)-Moores Cancer Center - San Diego
Colorado
- SCRI - Colorado Blood Cancer Institute (CBCI) - Denver
Florida
- Moffitt Cancer Center Magnolia Campus - Tampa
Iowa
- University of Iowa - Iowa City
Massachusetts
- Massachusetts General Hospital - Boston
Nebraska
- University of Nebraska - Omaha
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-02-15 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
What NCT06534060 shows while recruiting
NCT06534060 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 121-participant average among 9 other Lymphoma, T-Cell trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Lymphoma, T-Cell appearing as the primary indexed condition, and to 1 intervention - of which Genetic: MB-105 is the first listed.
NCT06534060 lists 12 locations in 11 states (Texas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06534060 about?
NCT06534060 is a clinical study titled "MB-105 in Patients With CD5 Positive T-cell Lymphoma". This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
What is the current status of trial NCT06534060?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2025-02-15. Estimated completion is 2029-12.
What conditions does trial NCT06534060 study?
This clinical trial studies the following conditions: Lymphoma, T-Cell.
What interventions are being tested in trial NCT06534060?
The interventions under investigation include: Genetic: MB-105 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06534060?
This trial is sponsored by March Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06534060 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, T-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06534060's enrollment target sits among peer trials
46 7th of 9 higher than 3 of 9 other Lymphoma, T-Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, T-Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
COMPLETED · Phase 2
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
RECRUITING · Phase 1
-
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI